Stockscreener 앱 받기
3.82
74.43%
1.63
시간 외 거래:
3.75
-0.07
-1.83%
전일 마감가:
$2.19
열려 있는:
$4.25
하루 거래량:
167.45M
Relative Volume:
61.00
시가총액:
$47.00M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+87.25%
1개월 성능:
+35.94%
6개월 성능:
+120.81%
1년 성능:
-85.80%
1일 변동 폭
$3.75
$6.3699
1주일 범위
$1.98
$6.3699
52주 변동 폭
$1.345
$28.06
Q 32 Bio Inc Stock (QTTB) Company Profile
명칭
Q 32 Bio Inc
전화
781-999-0232
주소
830 WINTER STREET, WALTHAM
QTTB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
3.82 | 26.95M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.60 | 110.02B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.11 | 82.00B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.56 | 59.61B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
894.90 | 56.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
211.41 | 44.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-02-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-12-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2024-12-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-10-24 | 개시 | Raymond James | Strong Buy |
| 2024-09-11 | 개시 | Wells Fargo | Overweight |
| 2024-06-17 | 개시 | Guggenheim | Buy |
| 2024-05-21 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Oppenheimer | Outperform |
| 2024-04-02 | 개시 | Piper Sandler | Overweight |
| 2023-07-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-02-22 | 재확인 | BTIG Research | Neutral |
| 2022-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-02-22 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-03-02 | 개시 | Stifel | Hold |
| 2020-12-14 | 재개 | H.C. Wainwright | Buy |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-02-24 | 개시 | Chardan Capital Markets | Buy |
| 2019-11-01 | 개시 | Oppenheimer | Perform |
| 2019-09-10 | 개시 | Robert W. Baird | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
모두보기
Q 32 Bio Inc 주식(QTTB)의 최신 뉴스
Q32 Bio Inc. (QTTB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook - ts2.tech
Q32 Bio Stock Soars On Selling Experimental Drug To Akeba For Up To $592M - Stocktwits
Q32 Bio Inc. (QTTB) Stock: Jumps on Akebia Acquisition of ADX-097 and Extended Runway - parameter.io
Synopsys, Moderna, Strategy, Q32 Bio, Wolfspeed: Stocks Making The Biggest Moves Today - Stocktwits
Q32 Bio Shares Soar After Offloading Phase 2 Complement Drug to Akebia - MSN
QTTB Stock Surges: Market Insight - StocksToTrade
Dow Dips 200 Points; Q32 Bio Shares Jump - inkl
Why Is Small-Cap Q32 Bio Stock Soaring On Monday? - inkl
Akebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal - MarketScreener
Q32 Bio stock rockets after selling Phase 2 complement inhibitor to Akebia - Investing.com Nigeria
Q32 Bio Sells Complement Inhibitor ADX-097 - citybiz
Q32 Bio sells complement inhibitor Adx-097 - MarketScreener
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront - TipRanks
Akebia Therapeutics (AKBA) Acquires Phase 2 Drug from Q32 Bio - GuruFocus
Q32 Bio Sells ADX-097 to Akebia Therapeutics - TipRanks
Akebia Announces Establishment of Rare Kidney Disease Pipeline - The Manila Times
Cash per share of Q32 Bio Inc – LSE:0T6G - TradingView
Q32 Bio Inc.Common Stock (Nasdaq:QTTB) Stock Quote - Markets Financial Content
Form 8-KCurrent report - ADVFN
Layoff Tracker: Novartis Cuts 550 Employees as Swiss Manufacturing Priorities Shift - BioSpace
What analysts say about Q32 Bio Inc stockEarnings Volatility Patterns & High Return Trading Plans - earlytimes.in
Q32 Bio Inc Stock Analysis and ForecastInstitutional Buying Trends & Small Entry Cost Portfolio - earlytimes.in
Is Q32 Bio Inc. stock supported by strong fundamentalsJuly 2025 Volume & Growth Focused Stock Reports - newser.com
How strong is Q32 Bio Inc. stock balance sheetMarket Sentiment Review & Growth Focused Investment Plans - newser.com
Tick level data insight on Q32 Bio Inc. volatilityJuly 2025 Recap & Fast Entry Momentum Alerts - newser.com
Is Q32 Bio Inc. stock reversal real or fakeInsider Buying & Expert Verified Stock Movement Alerts - newser.com
Is Q32 Bio Inc. stock attractive for income investorsTrade Volume Report & Daily Technical Stock Forecast Reports - newser.com
How Perimeter Solutions SA stock reacts to weak economyJuly 2025 Volume & Daily Growth Stock Tips - Newser
Q32 Bio Inc. stock trendline breakdown2025 Top Gainers & Fast Gain Stock Tips - newser.com
Intraday pattern recognizer results for Q32 Bio Inc.Market Movement Recap & High Accuracy Swing Entry Alerts - newser.com
EBITDA per share of Q32 Bio Inc – SWB:DB0 - TradingView
Q32 Bio (QTTB) Receives a Buy from Oppenheimer - The Globe and Mail
Q32 Bio (QTTB) Price Target Increased by 13.33% to 11.56 - Nasdaq
Trend analysis for Q32 Bio Inc. this weekTrade Analysis Report & Community Consensus Trade Signals - newser.com
How Q32 Bio Inc. stock reacts to oil pricesLong Setup & Accurate Entry/Exit Alerts - newser.com
Q32 Bio Inc. (QTTB) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Why Q32 Bio Inc. stock is a must watch in 2025Weekly Trade Report & Community Verified Trade Alerts - newser.com
Sentiment analysis tools applied to Q32 Bio Inc.Weekly Gains Summary & High Conviction Trade Alerts - newser.com
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q - GlobeNewswire
Q32 Bio: Q3 Earnings Snapshot - Stamford Advocate
Price momentum metrics for Q32 Bio Inc. explained2025 EndofYear Setup & Growth Focused Stock Pick Reports - newser.com
Q32 Bio Inc. Faces Financial Challenges Amid Development Efforts - TipRanks
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update - The AI Journal
Q 32 Bio Inc (QTTB) 재무 분석
Q 32 Bio Inc (QTTB)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Q 32 Bio Inc 주식 (QTTB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Violette Shelia M. | Chief Scientific Officer |
Aug 26 '25 |
Sale |
1.80 |
2,990 |
5,385 |
58,384 |
| Kalowski Lee | CFO and President |
Aug 26 '25 |
Sale |
1.80 |
4,240 |
7,636 |
49,010 |
0.30%
1.75%
자본화:
|
볼륨(24시간):